Latest Intravenous immunoglobulin Stories
Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage.
Every one in three patients needing a kidney transplant may never receive one because their bodies are unusually conditioned to assault a donated organ. Doctors are now trying to outsmart the immune system and save more "highly sensitized" patients.
A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah.
The FDA has approved Talecris Biotherapeutics's Gamunex, an immune globulin product for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Biotech company Pharming Group has announced that the FDA has authorized a clinical study with recombinant human C1 inhibitor for the treatment of antibody-mediated rejection in kidney transplantation.
Brief Report Lymphocytic choriomeningitis virus (LCMV) is a rodent-borne arenavirus found worldwide. House mice (Mus musculus) are the natural reservoir, but LCMV also can infect other wild, pet, and laboratory rodents (e.g., rats, mice, guinea pigs, and hamsters).
U.S. medical scientists say a drug commonly prescribed to treat immunodeficiencies has shown promise as a treatment for Alzheimer's disease.
LINCOLN, Neb., July 31 /PRNewswire/ -- Today, Grifols Biomat USA celebrates the grand opening of a new plasma donor center in Lincoln, Nebraska. The Lincoln center located on 2002 N Street is one of 60 Biomat USA center to be opened in the United States and the first in Nebraska.
CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimer's therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.